本文選題：良性前列腺增生 + 前列腺癌��； 參考：《延邊大學(xué)》2014年碩士論文

【摘要】：目的：探討良性前列腺增生及前列腺癌組織中腫瘤生物標(biāo)記物PCNA和NDRG1的表達(dá)及意義。判定PCNA和NDRG1在前列腺癌中的表達(dá)與發(fā)生發(fā)展過程中的診斷價值。探討聯(lián)合檢測PCNA和NDRG1對前列腺癌的診斷及意義。 方法：收集延邊大學(xué)附屬醫(yī)院2007-2012年期間治療前列腺癌及良性前列腺增生住院病人共78例,其中良性前列腺增生病人11例為正常對照組。前列腺癌病人67例,并按病理Gleason評分又分為低分化組49例和高分化組18例；按腫瘤學(xué)TNM分期將前列腺癌分為T1期、T2期、T3期、T4期,其中T1期和T2期分為一組,T3期和T4期分別一組,并兩組間進(jìn)行比較；將前列腺癌按有無骨轉(zhuǎn)移分別兩組,并兩組間進(jìn)行比較。全部數(shù)據(jù)采用免疫組化學(xué)方法進(jìn)行統(tǒng)計(jì)分析。 結(jié)果： 1.PCNA在良性前列腺增生和前列腺癌中的陽性表達(dá)具有顯著性差異,并有顯著統(tǒng)計(jì)學(xué)意義(P0.05)。PCNA在前列腺癌高分化組與低分化組的陽性表達(dá)具有顯著性差異,并有統(tǒng)計(jì)學(xué)意義(P0.05)；在腫瘤學(xué)TNM分期中T1～T2期總表達(dá)率與T3-T4期總表達(dá)具有顯著性差異,并有統(tǒng)計(jì)學(xué)意義(P0.05)；PCNA在前列腺癌有骨轉(zhuǎn)移和無骨轉(zhuǎn)移組織中表達(dá)有顯著性差異,具有統(tǒng)計(jì)學(xué)意義(P0.05)。 2.NDRG1在良性前列腺增生和前列腺癌中的陽性表達(dá)具有顯著性差異,并有統(tǒng)計(jì)學(xué)意義(P0.05)。NDRG1在前列腺癌高分化組與低分化組的陽性表達(dá)卻無顯著性差異,無統(tǒng)計(jì)學(xué)意義(P0.05)；在腫瘤學(xué)TNM分期中NDRG1在T1-T2期總表達(dá)率與T3-T4期總表達(dá)率無顯著性差異,并無統(tǒng)計(jì)學(xué)意義(P0.05)；PCNA在前列腺癌有骨轉(zhuǎn)移和無骨轉(zhuǎn)移組織中表達(dá)無顯著性差異,并無統(tǒng)計(jì)學(xué)意義(P0.05)。 3.PCNA和NDRG1在良性前列腺增生及前列腺癌中表達(dá)呈負(fù)相關(guān),并具有統(tǒng)計(jì)學(xué)意義(P0.05,r=-0.998)。 結(jié)論： 1.PCNA在前列腺癌組織中的表達(dá)水平顯著高于良性前列腺增生組織,隨病理Gleason評分、TNM分期及有骨轉(zhuǎn)移密的前列腺癌相關(guān),提示PCNA是診斷前列腺癌的重要腫瘤生物標(biāo)記物,其陽性表達(dá)程度代表腫瘤增殖活性、前列腺癌惡性程度及預(yù)后。 2.NDRG1在前列腺癌組織與良性前列腺增生組織中都呈現(xiàn)高表達(dá),但良性前列腺增生組織中表達(dá)明顯高于前列腺癌組織,與Gleason評分無顯著性差異,但隨Gleason評分增高有逐漸下降趨勢。提示,NDRG1可望成為診斷前列腺癌的新的腫瘤生物標(biāo)記物。但對于TNM分期及前列腺癌有無骨轉(zhuǎn)移NDRG1的表達(dá)無差異。 3.PCNA和NDRG1在前列腺癌的發(fā)生發(fā)展都有較高的特異性和敏感度,聯(lián)合檢測PCNA和NDRGl可能提高前列腺癌診斷率。
[Abstract]:Objective: to investigate the expression and significance of tumor biomarkers PCNA and NDRG1 in benign prostatic hyperplasia and prostate cancer. To evaluate the expression of PCNA and NDRG1 in prostate cancer and its diagnostic value. To explore the diagnostic value of combined detection of PCNA and NDRG1 in prostate cancer. Methods: a total of 78 patients with prostate cancer and benign prostatic hyperplasia were collected from Yanbian University affiliated Hospital from 2007 to 2012. Among them, 11 patients with benign prostatic hyperplasia (BPH) were as normal control group. 67 cases of prostate cancer were divided into low differentiation group (49 cases) and well-differentiated group (18 cases) according to pathological Gleason score, and prostate cancer was divided into T 1 stage and T 2 stage T 3 stage and T 4 stage according to TNM stage of oncology, in which T 1 stage and T 2 stage were divided into 3 stage and T 4 stage, respectively. Prostate cancer was compared with or without bone metastasis. All the data were analyzed by immunohistochemical method. Results: The positive expression of 1.PCNA in benign prostatic hyperplasia (BPH) and prostate cancer was significantly different. There was a significant difference between the total expression rate of T1~T2 and that of T3-T4 in TNM stage of oncology, and there was significant difference in the expression of T1~T2 between bone metastases and no bone metastases in prostate cancer, and there was a significant difference in the expression of P0.05 and P0.05in the stage of oncology, and there was a significant difference in the expression of P0.05 and P0.05 in prostate cancer with and without bone metastasis. It has statistical significance (P 0.05). There was significant difference in the positive expression of 2.NDRG1 between benign prostatic hyperplasia and prostate cancer, and there was no significant difference in the positive expression of 2.NDRG1 between highly differentiated and poorly differentiated prostate cancer. There was no significant difference in the total expression rate of NDRG1 between T1-T2 stage and T3-T4 stage in TNM stage of oncology, and there was no significant difference in the expression of NDRG1 in bone metastases and no bone metastases of prostate cancer. There was no statistical significance (P 0.05). The expression of 3.PCNA and NDRG1 in benign prostatic hyperplasia (BPH) and prostate cancer was negatively correlated, and there was a significant difference between P0.05r-0.998G (P 0.05). Conclusion: The expression of 1.PCNA in prostate cancer was significantly higher than that in benign prostatic hyperplasia (BPH). The expression of PCNA was correlated with the pathological Gleason score and bone metastasized prostate cancer, suggesting that PCNA was an important tumor biomarker in the diagnosis of prostate cancer. Its positive expression level represents tumor proliferative activity, malignant degree and prognosis of prostate cancer. The expression of 2.NDRG1 in prostate cancer tissues and benign prostatic hyperplasia tissues was higher than that in prostate cancer tissues. There was no significant difference between 2.NDRG1 and Gleason score, but with the increase of Gleason score, the expression of 2.NDRG1 decreased gradually. These results suggest that NDR G 1 may be a new tumor biomarker for the diagnosis of prostate cancer. However, there was no difference in the expression of NDRG1 in TNM stage and prostate cancer with or without bone metastasis. Both 3.PCNA and NDRG1 have high specificity and sensitivity in the development of prostate cancer. Combined detection of PCNA and NDRGl may improve the diagnosis rate of prostate cancer.
【學(xué)位授予單位】：延邊大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2014
【分類號】：R737.25

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 王國慶,李明眾,徐瑞;宮頸癌相關(guān)基因的研究進(jìn)展[J];癌變.畸變.突變;2004年03期

2 孫衍增,牛兆山;P53蛋白和增殖細(xì)胞核抗原在前列腺癌中的表達(dá)及意義[J];青島大學(xué)醫(yī)學(xué)院學(xué)報;2001年04期

3 況南珍;傅穎媛;黃紅衛(wèi);王福財(cái);曾小平;;VEGF、PCNA及Survivin與膀胱癌病理分級、臨床分期的關(guān)系[J];重慶醫(yī)學(xué);2012年07期

4 羅家倫;劉功傳;徐慧琴;程光華;郝加虎;;PSA、PSAD在前列腺癌與前列腺增生鑒別診斷中的價值[J];放射免疫學(xué)雜志;2006年02期

5 胡廣平;畢學(xué)成;何慧嬋;葉永康;韓兆冬;梁宇翔;鐘惟德;;前列腺癌中Ki-67的表達(dá)及其意義[J];廣州醫(yī)藥;2008年05期

6 柴偉;張國建;張?jiān)撇?任鵬濤;趙晶;王鳳安;;NDRG-1、WWOX及P53基因在胃癌組織中的表達(dá)及臨床意義[J];昆明醫(yī)學(xué)院學(xué)報;2009年05期

7 董昌元;王玲;王賢明;易建華;姚啟盛;;前列腺癌組織中PCNA、MVD表達(dá)與彩超血流檢測的研究[J];中國臨床醫(yī)學(xué)影像雜志;2007年01期

8 杜林棟;王文營;李炫昊;;前列腺癌診斷標(biāo)志物研究現(xiàn)狀[J];臨床泌尿外科雜志;2009年08期

9 曾翔;梁勇;付光慶;;IGF-1、PCNA和Caspase3在前列腺癌組織的表達(dá)及臨床意義[J];海南醫(yī)學(xué);2013年19期

10 翟振興;王志平;;前列腺癌基因治療的進(jìn)展[J];現(xiàn)代泌尿生殖腫瘤雜志;2009年05期

，

本文編號：1958424